ENDRA Life Sciences Inc.

NDRA Healthcare Diagnostics & Research

In the quarter to June 2026, EPS grew 107.0% and free cash flow grew 15.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

4.74 0.36 −7.06%
Market cap
$7.7M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
6/9
Altman Z
−5.26
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
7.10 0.64 1.29 1.31
Net Debt/EBITDA
3.84 0.17 0.48 0.60
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.71) (0.93) (5.86) (1.53)
Book value per Share
4.77 1.49 2.87 0.23
Free Cash Flow
(0.95) (1.12) (4.61) (1.16)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates